By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
.
A substance used for its actions on the gastrointestinal system, including enhancing digestion, reducing gastric acidity, and regulating gastrointestinal motility and water flow. The digestive system’s organs, such as the liver, biliary tract, and pancreas, as well as disorders that may impact those organs, are cared for and treated with the aid of medications for the gastrointestinal system.
The functions of medications that influence the gastrointestinal system are the subject of gastrointestinal (GI) pharmacology. These medications restore GI tract function to normal.
Proton pump inhibitors that require a prescription. Esomeprazole (Nexium), lansoprazole (Peracid), omeprazole (Prilosec), pantoprazole (Protonix), rabeprazole (Aciphex), and DE lansoprazole are a few of these (Dexilant) H-2 blockers that require a prescription.
The Global Prescription Gastrointestinal Drugs market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Vedolizumab, a medication for the digestive system, is now available in India thanks to the Japanese pharmaceutical company Takeda. Vedolizumab, a popular biologic medication, will soon be available in India as a part of Takeda India’s gastrointestinal (GI) portfolio.
Takeda India is a subsidiary of the renowned Japanese pharmaceutical company Takeda Pharmaceutical Corporation. After hematology, genetic diseases, and immunology, gastrointestinal (GI) disorders are Takeda’s second therapeutic focus in India.
Vedolizumab, which will be marketed as Kynteles in India, is used to treat chronic inflammatory bowel illnesses (IBD) such Ulcerative Colitis and Crohn’s Disease. According to the manufacturer, patients with moderate to severe inflammatory bowel disease responded favorably to Kennels’ safety and efficacy outcomes (IBD).
Although the corporation withheld the pricing, it said that it will be set in accordance with the accessibility and affordability of the Indian market.
The top-notch R&D team at Takeda is passionate and unwaveringly committed to creating ground-breaking treatments. They work together in the areas where patients have the greatest needs, establishing alliances that will allow them to have a bigger impact on patients’ lives both now and in the future.
Takeda is advancing clinical care and scientific research in collaboration with other parties, including researchers, patient organizations, and will keep looking for improved ways to treat people with GI and liver illnesses.
